Cocoa reduces CVD mortality by almost 30% over a 6 year period, and its anti-inflammatory effect may partially explain why.
Results of the COSMOS randomized trial at Harvard Medical School and Brigham and Women’s Hospital in Boston.
Quoted:
“Between 2014 and 2020, Brigham and Women's Hospital led the COSMOS trial, a large-scale, randomized, double-blind, placebo-controlled clinical trial with 21,442 participants over 60 years old, finding that cocoa extract supplementation decreased cardiovascular disease mortality by 27%.
In this new study, researchers collected and analyzed blood samples of 598 COSMOS participants to measure several inflammaging biomarkers: three pro-inflammatory proteins (hsCRP, IL-6, and TNF-α), one anti-inflammatory protein (IL-10), and one immune-mediating protein (IFN-γ).
Comparing changes in these biomarkers measured at baseline, one, and two years follow-up, hsCRP levels decreased by 8.4% each year compared with placebo, while the other biomarkers remained relatively consistent or increased modestly.
The decrease in hsCRP may help explain the cardio-protective effects seen with cocoa extract supplement in the larger COSMOS trial, where participants experienced a reduction in cardiovascular disease death.”


